Patents Examined by Cecilia J. Tsang
  • Patent number: 8603966
    Abstract: Described herein are compounds that comprise amino acids and their pharmaceutical compositions. Methods used to administer the compounds are described. Screening methods including those for determining translocation and leakage are also provided.
    Type: Grant
    Filed: February 27, 2010
    Date of Patent: December 10, 2013
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: William C. Wimley, Jessica R. Marks
  • Patent number: 8603986
    Abstract: Peptides comprising a cadherin cell adhesion recognition (CAR) sequence, and compositions comprising such peptides, are provided. Methods of using such peptides for modulating cadherin-mediated processes in a variety of therapeutic contexts are also provided. Methods are also provided for identifying compounds that are capable of modulating cadherin-mediated processes.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: December 10, 2013
    Assignee: McGill University
    Inventors: Orest W. Blaschuk, Emmanuelle Marie-Madeleine Devemy
  • Patent number: 8603968
    Abstract: Cyclic peptides having a random alternation of L-?-aminoacyl residues and aza-?3-aminoacyl residues and their uses.
    Type: Grant
    Filed: October 8, 2008
    Date of Patent: December 10, 2013
    Assignees: Centre National de la Recherche Scientifique, Universite de Rennes I
    Inventors: Mathieu Laurencin, Céline Zatylny-Gaudin, Joël Henry, Michéle Baudy Floc'H
  • Patent number: 8598146
    Abstract: The present invention provides novel cell-based and animal-based assays for determining antagonists of PKC? and uses of the isolated antagonist compounds for modulating insulin clearance and secretion. The invention also provides novel animals and cells such as animals and cells suitable for use in the assays.
    Type: Grant
    Filed: September 16, 2004
    Date of Patent: December 3, 2013
    Assignee: Garvan Institute of Medical Research
    Inventors: Trevor John Biden, Carsten Schmitz-Peiffer
  • Patent number: 8598313
    Abstract: In alternative embodiments, the invention provides apratoxin F and apratoxin G compounds, which include apratoxin F and apratoxin G stereoisomers, derivatives and analogs compositions and methods. In alternative embodiments, the invention provides pharmaceutical compositions and formulations comprising apratoxin F (compound 6 of FIG. 1) and apratoxin G (compound 7 of FIG. 1) and their stereoisomers, derivatives and analogs. In alternative embodiments, pharmaceutical compositions and formulations of the invention are administered in an amount sufficient to treat, prevent and/or ameliorate a disease or condition that can be ameliorated by decreasing or inhibiting cell growth, e.g., pathological, uncontrolled or unwanted cell growth, e.g., a cancer or a metastases, or any disease or condition (e.g., allergy) or infection having a hyperproliferative cell growth component.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: December 3, 2013
    Assignee: The Regents of the University of California
    Inventors: William H. Gerwick, Kevin Tidgewell, Frederick A. Valeriote
  • Patent number: 8598316
    Abstract: The present invention provides a conjugate that contains a therapeutic moiety linked to a homing peptide or peptidomimetic which selectively homes to vasculature of pre-malignant dysplastic skin and which includes the amino acid sequence SRPRR (SEQ ID NO: 1) or a conservative variant or peptidomimetic thereof. The present invention further provides a conjugate containing a therapeutic moiety linked to a homing peptide or peptidomimetic which selectively homes to vasculature of malignant skin and which includes the amino acid sequence CGKRK (SEQ ID NO: 6) or the amino acid sequence CDTRL (SEQ ID NO: 7), or a conservative variant or peptidomimetic of one of these sequences.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: December 3, 2013
    Assignees: Sanford-Burnham Medical Research Institute, The Regents of the University of California
    Inventors: Douglas Hanahan, Erkki Ruoslahti
  • Patent number: 8598113
    Abstract: This invention relates to polypeptides which bind to EGFR family receptors and to applications of those polypeptides in medicine, veterinary medicine, diagnosis diagnostics and imaging.
    Type: Grant
    Filed: July 16, 2012
    Date of Patent: December 3, 2013
    Assignee: Affibody AB
    Inventors: Fredrik Nilsson, Tove Eriksson, Andreas Jonsson, Stefan Stahl, Mikaela Friedman
  • Patent number: 8592551
    Abstract: Discrete and diffuse defects in a surface are detected. Discrete defects that may compromise the performance may be repaired.
    Type: Grant
    Filed: October 19, 2005
    Date of Patent: November 26, 2013
    Assignee: Massachusetts Institute of Technology
    Inventors: Asher K. Sinensky, Angela M. Belcher
  • Patent number: 8592367
    Abstract: The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from the N-terminal part of the peptide, in particular peptides having the SEQ IDS NO: 464 to 925, for the preparation of a drug intended for the treatment of human, animal or plant diseases induced by microorganisms, wherein the peptides have a broad-spectrum and fast antibiotic activity, in particular killing of the bacteria within 1 to 3 hours.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: November 26, 2013
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Eva Kondorosi-Kuzsel, Peter Mergaert, Willem Van de Velde, Gergely Maroti, Attila Farkas, Attila Kereszt
  • Patent number: 8592369
    Abstract: The present invention relates generally to the field of neuronal health and neuronal protection. One embodiment of the present invention relates to a composition that can be used for the protection of the enteric nervous system from neurodegeneration. Disorders linked to an impaired enteric nervous system can be treated or prevented by the administration of lactoferrin containing compositions according to the present invention.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: November 26, 2013
    Assignee: Nestec S.A.
    Inventors: Magali Faure, Bing Wang, Jeroen Schmitt
  • Patent number: 8586570
    Abstract: Peptidyl sensors comprise a metal-binding peptide and one or two kinase recognition sequences with a hydroxyamino acid that can be phosphorylated in the presence of a kinase.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: November 19, 2013
    Assignee: Massachusetts Institute of Technology
    Inventors: Barbara Imperiali, Elvedin Lukovic, Dora Carrico-Moniz
  • Patent number: 8586542
    Abstract: The invention provides small molecule mimics of the Smac peptide that are dimer- or dimer-like compounds having two amide-containing domains connected by a linker. These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and autoimmune disorders.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: November 19, 2013
    Assignee: Joyant Pharmaceuticals, Inc.
    Inventors: Gunnar J. Hanson, David Thomas, Nizal Chandrakumar, Susan Harran
  • Patent number: 8586544
    Abstract: The present invention relates to a cell-permeable endostatin recombinant protein in which a macromolecule transduction domain (MTD) is fused to an angiogenesis inhibitor (angiogenesis inhibitor) endostatin; a polynucleotide encoding the cell-permeable endostatin recombinant protein; an expression vector for the cell-permeable endostatin recombinant protein; and a pharmacological composition for an anti-cancer preparation with improved inhibitory activity against angiogenesis in cancer, which contains the cell-permeable endostatin recombinant protein as an active component.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: November 19, 2013
    Assignees: Procell Therapeutics Inc.
    Inventors: Daewoong Jo, Jong Min Lee, Kyoungho Park, Minh Tam Duong
  • Patent number: 8580731
    Abstract: An insulin-gold nanocluster, a pharmaceutical composition for treating diabetes comprising the insulin-gold nanocluster, and a method for detecting adipose cells in a tissue by using the insulin-gold nanocluster are provided. Herein, the insulin-gold nanocluster of the present invention comprises: a gold nanocluster, and insulin connecting to the gold nanocluster, wherein the insulin-gold nanocluster emits red fluorescence at maximized wavelength of 670 nm.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: November 12, 2013
    Assignee: National Taiwan University
    Inventors: Pi-Tai Chou, Chien-Liang Liu, Yun-Chen Chien
  • Patent number: 8580749
    Abstract: Embodiments of the present invention are directed to a coated cell comprising a therapeutic cell and a plurality of targeting complexes coating the therapeutic cell and each of said targeting complexes comprising a homing molecule, a lipid moiety, and a spacer having from about 1 to about 10 amino acids and covalently linking the homing molecule to the lipid moiety and wherein the lipid moiety is non-covalently attached to the therapeutic cell. In some embodiments, the therapeutic cell is a stem cell. Embodiments of the invention are directed to methods of coating a therapeutic cell. Embodiments of the invention are directed to methods of treating diseases of the vasculature.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: November 12, 2013
    Assignee: Cell Targeting, Inc.
    Inventors: Joseph Wagner, Randell Young, David Fink
  • Patent number: 8575089
    Abstract: The present invention relates to a composition containing Substance P for preventing or treating an inflammation. The composition containing Substance P according to the present invention exhibits the effect of decreasing leukocytes, neutrophils and hematopoietic stem cells in a blood, which are associated with the inflammation, and of increasing anti-inflammatory cytokines, regulatory T-lymphocytes, anti-inflammatory macrophages and the like, thereby terminating inflammatory response at an early stage, and is thus highly effective in preventing and treating the inflammation caused by a non-traumatic, traumatic, infectious or ischemic retinal injury.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: November 5, 2013
    Assignee: University-Industry Cooperation Group of Kyung Hee
    Inventors: Young Sook Son, Hyun Sook Hong, Do Yeon Kim, Eun Kyung Lee
  • Patent number: 8575096
    Abstract: The invention is related to fast acting insulin analogues which can form soluble mix-tures (pre-mixed or self-mixed) with long acting insulin analogues. The fast action is achieved through monomerizing substitutions/deletions in the C-terminus of the B-chain of human insulin and the mixability with long acting insulin analogues is achieved through a substitution of the Zn-binding His in position B10 of human insulin with a Gln amino acid residue. In one embodiment the invention is related to fast acting insulin analogues in which at least one of the natural amino acid residues in position B22-B30 in the human B-chain has been substituted with another amino acid residue having the effect of promoting formation of the monomeric form of insulin, the His amino acid residue in position 10 in the B-chain is substituted with a Gln and wherein further one or more of the amino acid residues in position B22-B30 optionally have been deleted.
    Type: Grant
    Filed: August 12, 2008
    Date of Patent: November 5, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Helle Birk Olsen, Thomas Børglum Kjeldsen, Per Balschmidt, Tine Glendorf, Svend Havelund
  • Patent number: 8569226
    Abstract: A dodecamer peptide, and its modified variant, having a repeating glycine-lysine sequence was created and found to bind with high affinity to oxide surfaces and certain activated polymeric surfaces. Reversible binding characteristics of the peptides were demonstrated. The peptides were integrated with proteins, cells and fusion proteins to provide attachment of the proteins, cells and fusion proteins to solid material structures. The peptides can be used to functionalize surfaces of components within mechanical, in mechanical, biomechanical, micro fluidic, electronic, bioelectronic, bio-optical, and biochemical devices. Experiments were carried out to assess functionalization and reusability of a suspended mass resonator's cantilever.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: October 29, 2013
    Assignee: Massachusetts Institute of Technology
    Inventors: Eric Mark Krauland, Stephen Kottmann, Roberto Juan Barbero, Angela Belcher
  • Patent number: 8569453
    Abstract: Particular compounds having a fluorene skeleton are superior in broad utility and stability, as a protecting reagent for liquid phase synthesis of amino acids and/or peptides.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: October 29, 2013
    Assignee: Ajinomoto Co., Inc.
    Inventor: Daisuke Takahashi
  • Patent number: 8569245
    Abstract: This invention relates to grassystatins A, B and C, and their isolated or purified forms. The compounds of the invention are useful as aspartic protease, gamma secretase, or metalloprotease inhibitors. Methods of using the compounds and compositions thereof are also disclosed.
    Type: Grant
    Filed: June 26, 2010
    Date of Patent: October 29, 2013
    Assignees: University of Florida Research Foundation, Inc., Smithsonian Institution
    Inventors: Hendrik Luesch, Valerie J. Paul, Jason C. Kwan